NovaBay Pharmaceuticals Adds Five Top Ophthalmologiststo its
Ophthalmic Advisory Board

The new board members are a testament to the fact that NovaBay’s
i-Lid Cleanser is an important advance in eye care for a growing number
of doctors

August 28, 2014 07:00 AM Eastern Daylight Time

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay®
Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company
focusing on the development and commercialization of its non-antibiotic
anti-infective products,announced today that it has added four
new members to its Ophthalmic Advisory Board (OAB), who will join the ten
existing members of the board. The board oversees the development,
marketing and medical use of NovaBay’s i-LidTM
Cleanser and other eye care products.

NovaBay has also seen great interest and acceptance of i-Lid Cleanser
from the Optometry community and will soon announce its success in
establishing an Optometry Advisor Board composed of distinguished
Doctors of Optometry from around the U.S.

The new members are Dr.
Richard L. Lindstrom, founder and attending surgeon of Minnesota Eye
Consultants and Adjunct Professor Emeritus at the University of
Minnesota Department of Ophthalmology; Dr.
Edward J. Holland, Director of Cornea Services at the Cincinnati Eye
Institute and Professor of Ophthalmology at the University of
Cincinnati; Dr.
Terry Kim, Professor of Ophthalmology at Duke University School of
Medicine, and Associate Director of the Corneal and External Disease
Service and Refractive Surgery Service at the Duke University Eye
Center; Dr.
Francis Mah, Director of Cornea and External Disease and Co-Director
of Refractive Surgery, Scripps Clinic Medical Group, La Jolla, CA;
Russell N. Van Gelder, M.D., PhD., University of Washington Professor
and Chair of the Department of Ophthalmology; and Dr.
Randal Pham, Director of The Advanced Surgery Medical Center, San
Jose, CA and a Fellow of the American Academy of Ophthalmology, American
College of Surgeons and the American Society of Ophthalmic Plastic &
Reconstructive Surgery.

The Ophthalmic Advisory Board members have shown in their own practices
that i-Lid Cleanser is an important advance in the treatment of such
conditions as blepharitis and dry-eye syndrome, from which an estimated
40 million Americans suffer. Current advisory board member Stephen
Wilmarth, M.D., Refractive and Cataract Surgeon and Medical
Director, Ophthalmic Surgery, at South Placer Surgery Center in the
Sacramento, CA area, described i-Lid Cleanser as “a whole new way of
dealing with germs. I believe it can make a real contribution to
alleviating human suffering.”

“The fact that NovaBay has been able to attract the nation’s top
ophthalmologists to its Ophthalmic Advisory Board is a testament to the
medical benefits that i-Lid Cleanser brings,” said ophthalmologist Kathryn
Najafi-Tagol, MD, Founder and Medical Director of the Eye Institute
of Marin; co-developer of i-Lid Cleanser and an OAB member. “In my own
practice, I find that the product has brought major improvements in
treatment and patients’ quality of life.”

Dr. Najafi-Tagol and many of the other members of the OAB use i-Lid
Cleanser with patients who suffer from blepharitis, a condition where Staphylococci
bacteria grow on eyelids, causing swelling, redness, inflammation,
irritation and a crusty build-up. Patients
who’ve had these symptoms for years report that i-Lid Cleanser has
finally brought relief from the often-painful condition. Lab tests also
show that, in addition to killing bacteria, i-Lid Cleanser neutralizes
the toxins produced by bacteria. That is why many doctors believe it is
effective in dry eye syndrome, which typically results when Staph
bacteria and the secretion of bacterial toxins cause the meibomian
glands to be obstructed by thick waxy secretions. i-Lid Cleanser is now
being used to remove both the bacteria and the bacterial toxins.

“All members of our Ophthalmic Advisory Board are national leaders in
eye care,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. “We are
grateful that they are supporting our efforts to bring i-Lid Cleanser to
the millions of Americans who can benefit from the product.”

Forward-looking Statements

This release contains forward-looking statements and opinions
regarding the commercial and clinical potential of i-Lid Cleanser, which
are based upon the company’s current expectations, assumptions,
estimates, projections and beliefs.The words “believe,”
“estimated,” and “expectation,” are intended to identify the
forward-looking statements.Forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and adverse
from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such differences
include, but are not limited to, risks and uncertainties relating to the
actual effectiveness of NovaBay products and unexpected adverse side
effects or inadequate therapeutic efficacy of i-Lid Cleanser, and the
risk that potential customers will not perceive the benefits of i-Lid
Cleanser to be the same as NovaBay believes. Other risks relating to
NovaBay and its products, including risks that could cause results to
differ materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay's latest Form 10-K and
Form 10-Q filings with the Securities and Exchange Commission,
especially under the heading "Risk Factors." The forward-looking
statements in this release speak only as of this date, and NovaBay
disclaims any intent or obligation to revise or update publicly any
forward-looking statement except as required by law.